Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tiziana Life SciencesTLSA -0.45%23 EV-to-EBITDA is -7.50 as of Jul. 17, 2026. GuruFocus rates TLSA with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 398 Biotechnology companies, Tiziana Life Sciences ranks worse than 251256.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tiziana Life Sciences's enterprise value is $136.43 Mil.
Tiziana Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-18.18 Mil. Therefore, Tiziana Life Sciences's EV-to-EBITDA for today is -7.50.
The historical rank and industry rank for Tiziana Life Sciences's EV-to-EBITDA or its related term are showing as below:
TLSA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.57 Med: 0 Max: 0
Current: -7.5
TLSA's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 12.29
vs TLSA: -7.50
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Tiziana Life Sciences (NAS:TLSA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tiziana Life Sciences's PE Ratio (TTM) for today is calculated as:
Tiziana Life Sciences's share price for today is $1.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tiziana Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Tiziana Life Sciences EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Tiziana Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tiziana Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tiziana Life Sciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tiziana Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tiziana Life Sciences's EV-to-EBITDA falls into.
Tiziana Life Sciences's current Enterprise Value is $136.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tiziana Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-18.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tiziana Life Sciences (TLSA) has a EV-to-EBITDA of -7.50 as of Jul. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tiziana Life Sciences. According to the industry distribution chart, Tiziana Life Sciences ranks #999999 out of 398 companies in the Biotechnology industry.
Is Tiziana Life Sciences' EV-to-EBITDA too high?
Tiziana Life Sciences' current EV-to-EBITDA is -7.50. Based on the distribution chart, Tiziana Life Sciences ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tiziana Life Sciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Tiziana Life Sciences' EV-to-EBITDA compare to SPRB and MIST?
According to the Biotechnology industry distribution chart, Tiziana Life Sciences ranks #999999 out of 398 companies for EV-to-EBITDA. This places Tiziana Life Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 12.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.29, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tiziana Life Sciences. For the Biotechnology industry, the median EV-to-EBITDA is 12.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tiziana Life Sciences's current EV-to-EBITDA is -7.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tiziana Life Sciences stock overvalued right now?
Tiziana Life Sciences (TLSA) has a current EV-to-EBITDA of -7.50. The current EV-to-EBITDA is -7.50. Tiziana Life Sciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Tiziana Life Sciences (TLSA), the current EV-to-EBITDA is -7.50 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
23GF Score
Get the complete analysis for TLSA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSA has been successfully added to your 
